Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients

Journal of Thoracic Oncology

Volumn 9, Issue 5, 2014, Pages 733-737

  Gridelli, Cesare ^a   Novello, Silvia ^b   Zilembo, Nicoletta ^c   Luciani, Andrea ^d   Favaretto, Adolfo Gino ^e   De Marinis, Filippo ^f   Genestreti, Giovenzio ^g   Crinò, Lucio ^h   Grossi, Francesco ⁱ   Caffo, Orazio ^j   Ferraù, Francesco ^k   Cruciani, Giorgio ^l   Brandes, Alba Ariela ^m   Galetta, Domenico ⁿ   Barni, Sandro ^o   Fasola, Gianpiero ^p   Cerea, Giulio ^q   Ferrari, Silvia ^r   Iannacone, Claudio ^s   Ciardiello, Fortunato ^t  

^a S G MOSCATI HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SAN PAOLO HOSPITAL   (Italy)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^h SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

ⁱ UNIVERSITY OF GENOA   (Italy)

^j SANTA CHIARA HOSPITAL   (Italy)

^k San Vincenzo Hospital ^*  (Italy)

^l SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^m Azienda USL di Bologna   (Italy)

ⁿ NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^o TREVIGLIO HOSPITAL   (Italy)

^p UNIVERSITY HOSPITAL OF UDINE   (Italy)

^q OSPEDALE NIGUARDA CA GRANDA   (Italy)

^r ASTRAZENECA   (United Kingdom)

^s LB Research   (Italy)

^t SECOND UNIVERSITY OF NAPLES   (Italy)

more..

Author keywords

Elderly; Gemcitabine; Non small cell lung cancer; Vandetanib

Indexed keywords

GEMCITABINE; PLACEBO; VANDETANIB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BRAIN ISCHEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ELDERLY CARE; FATIGUE; FEMALE; FEVER; HUMAN; HYPOKALEMIA; LUNG EDEMA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FAILURE; THORAX PAIN; THROMBOCYTOPENIA; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PIPERIDINES; PLACEBOS; QUINAZOLINES; SURVIVAL RATE;

EID: 84899049029     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000120     Document Type: Article

References (13)

1. Sathornsumetee S Rich JN. Vandetanib a novel multitargeted kinase inhibitor in cancer therapy. Drugs Today (Barc) 2006;42:657-670.
2. Lee JS Hirsh V Park K et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized double-blind phase III trial (ZEPHYR). J Clin Oncol 2012;30:1114-1121.
3. Natale RB Thongprasert S Greco FA et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced nonsmall-cell lung cancer. J Clin Oncol 2011;29:1059-1066.
4. Herbst RS Sun Y Eberhardt WE et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind randomised phase 3 trial. Lancet Oncol 2010;11:619-626.
5. de Boer RH Arrieta O Yang CH et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized double-blind phase III trial. J Clin Oncol 2011;29: 1067-1074.
6. Quoix E. Optimal pharmacotherapeutic strategies for elderly patients with advanced non-small cell lung cancer. Drugs Aging 2011;28: 885-894.
7. Gridelli C Aapro M Ardizzoni A et al. Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J Clin Oncol 2005;23:3125-3137.
8. Des Guetz G Uzzan B Nicolas P Valeyre D Sebbane G Morere JF. Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: a meta-analysis. Crit Rev Oncol Hematol 2012;84:340-349.
9. Gridelli C Perrone F Gallo C et al.; MILES Investigators. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
10. Rosen AC Wu S Damse A Sherman E Lacouture ME. Risk of rash in cancer patients treated with vandetanib: systematic review and metaanalysis. J Clin Endocrinol Metab 2012;97:1125-1133.
11. Heymach JV Johnson BE Prager D et al. Randomized placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007;25:4270-4277.
12. Frampton JE. Vandetanib: in medullary thyroid cancer. Drugs 2012;72:1423-1436.
13. Qi WX Tang LN He AN Shen Z Yao Y. The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials. Lung 2011;189:437-443.